Close Menu

Caveat Emptor

The UK's Times Online reports on the growing market of companies like 23andMe, kicking off with this straight-to-the heart statement: "Leading genetic testing companies are providing clients with widely divergent and inaccurate predictions of their chances of developing serious diseases." The author has used the services of 23andMe, DecodeMe, and British provider GeneticHealth, getting in return "contradictory assessments of the risk I faced of developing illnesses, including Alzheimer's and glaucoma, and a confused verdict on my risk of suffering heart problems."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.